[Skip to Content]
[Skip to Content Landing]
June 1968

Clinical Trial of Live Attenuated Rubella Virus Vaccine, HPV-77 Strain

Author Affiliations

New York
From the Department of Pediatrics, New York University School of Medicine, and the Willowbrook State School, Staten Island, NY.

Am J Dis Child. 1968;115(6):655-657. doi:10.1001/archpedi.1968.02100010657003

IN 1966, Parkman, Meyer, and their colleagues described preliminary vaccine trials with a strain of rubella virus which had been attenuated by 77 passages in primary African green monkey kidney (AGMK) tissue culture.1,2 This strain, designated HPV-77, exhibited desirable qualities of immunogenicity and obvious attenuation in man. The present report describes our experience with HPV-77 virus in a series of vaccine trials which involved 48 children.

Materials and Methods  Vaccine.—The details of the preparation and safety testing of HPV-77 vaccine have been described by Meyer et al.1,2 The vaccine was supplied in single-dose vials which were stored at −65 C until use. Each vaccinated child received rubella vaccine (HPV-77), 0.5 ml subcutaneously. This dose represented 500 tissue culture interfering doses50 (TCID50), based on a titration in primary AGMK tissue culture using echovirus type 11 challenge.3Study Population and Experimental Design.—The 48 children were admitted

First Page Preview View Large
First page PDF preview
First page PDF preview